Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates

分组1 - Voyager Therapeutics reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.38, and an improvement from a loss of $0.51 per share a year ago, resulting in an earnings surprise of 52.63% [1] - The company achieved revenues of $29.58 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 156.75%, compared to revenues of $4.85 million in the same quarter last year [2] - Voyager Therapeutics has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed the market, losing about 5.6% since the beginning of the year, while the S&P 500 has gained 8.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $10.77 million, and for the current fiscal year, it is -$1.39 on revenues of $52.72 million [7] - The Medical - Biomedical and Genetics industry, to which Voyager Therapeutics belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]